Vanguard Group Inc. Decreases Stake in OrthoPediatrics Corp. (NASDAQ:KIDS)

Vanguard Group Inc. lessened its holdings in shares of OrthoPediatrics Corp. (NASDAQ:KIDS) by 3.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 923,890 shares of the company’s stock after selling 32,165 shares during the quarter. Vanguard Group Inc. owned 3.81% of OrthoPediatrics worth $21,416,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of KIDS. Mutual of America Capital Management LLC raised its position in shares of OrthoPediatrics by 57.1% in the 4th quarter. Mutual of America Capital Management LLC now owns 169,021 shares of the company’s stock valued at $3,918,000 after purchasing an additional 61,412 shares in the last quarter. Barclays PLC increased its stake in shares of OrthoPediatrics by 319.3% in the third quarter. Barclays PLC now owns 25,298 shares of the company’s stock worth $686,000 after buying an additional 19,264 shares during the last quarter. HighTower Advisors LLC acquired a new stake in OrthoPediatrics in the fourth quarter valued at $268,000. Geode Capital Management LLC boosted its stake in OrthoPediatrics by 2.1% during the 3rd quarter. Geode Capital Management LLC now owns 391,492 shares of the company’s stock valued at $10,615,000 after acquiring an additional 7,972 shares during the last quarter. Finally, AlphaCentric Advisors LLC acquired a new position in OrthoPediatrics during the 4th quarter worth $171,000. Hedge funds and other institutional investors own 69.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $42.00 target price on shares of OrthoPediatrics in a report on Wednesday, April 9th. Stifel Nicolaus reduced their price objective on OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, March 5th. Truist Financial reduced their price target on shares of OrthoPediatrics from $26.00 to $24.00 and set a “hold” rating on the stock in a research report on Friday, April 11th. Finally, Lake Street Capital assumed coverage on shares of OrthoPediatrics in a research note on Monday, April 7th. They set a “buy” rating and a $37.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $37.00.

OrthoPediatrics Stock Down 0.0 %

KIDS opened at $20.97 on Wednesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.17 and a quick ratio of 3.68. OrthoPediatrics Corp. has a 12 month low of $20.37 and a 12 month high of $35.99. The stock’s 50 day moving average price is $24.07 and its 200 day moving average price is $24.68. The stock has a market cap of $509.30 million, a P/E ratio of -17.05 and a beta of 1.17.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. The business had revenue of $52.67 million for the quarter, compared to analysts’ expectations of $51.16 million. OrthoPediatrics had a negative net margin of 15.00% and a negative return on equity of 5.78%. During the same period in the previous year, the business earned ($0.23) earnings per share. As a group, research analysts predict that OrthoPediatrics Corp. will post -0.93 earnings per share for the current year.

Insider Activity

In related news, General Counsel Daniel J. Gerritzen sold 5,310 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total value of $132,006.60. Following the sale, the general counsel now directly owns 110,767 shares in the company, valued at $2,753,667.62. The trade was a 4.57 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO David R. Bailey sold 6,620 shares of the stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $164,573.20. Following the sale, the chief executive officer now directly owns 319,155 shares of the company’s stock, valued at approximately $7,934,193.30. This represents a 2.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 23,732 shares of company stock worth $589,978. 31.80% of the stock is owned by company insiders.

OrthoPediatrics Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.